10 completed, 1 unknown. 9 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 9 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Yuhong Li: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients. mFOLFORINOX - Pancreatic Cancer Resectable | Phase 2 | Completed | Yuhong Li | 80 | 2020-01-31 | 2023-02-15 |
| Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC C225+CPT-11 - Metastatic Colorectal Cancer | Phase 2 | Completed | Yuhong Li | 35 | 2020-01-31 | 2023-02-15 |
| Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma Paclitaxel+Cisplatin+5fluorouracil - Esophageal Squamous Cell Carcinoma | Phase 2 | Completed | Yuhong Li | 46 | 2016-10-01 | 2023-02-17 |
| Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment Apatinib Mesylate - Esophageal Squamous Cell Carcinoma | Phase 2 | Completed | Yuhong Li | 43 | 2016-08-01 | 2023-02-16 |
| Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer Paclitaxel+Nedaplatin+Endostar - Esophageal Squamous Cell Carcinoma | Phase 2 | Completed | Yuhong Li | 52 | 2015-01-01 | 2023-02-16 |
| Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer GM1, placebo, mFOLFOX6 or XELOX - Colorectal Cancer, Chemotherapy-induced Neutropenia | Phase 3 | Completed | Yuhong Li | 196 | 2014-09-01 | 2019-10-07 |
| A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis mFOLFOX6, HAI - Metastatic Colorectal Cancer | Phase 3 | Unknown | Yuhong Li | 142 | 2014-03-01 | 2024-03-04 |
| Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy Icotinib Hydrochloride - Esophageal Squamous Cell Carcinoma | Phase 2 | Completed | Yuhong Li | 50 | 2013-10-01 | 2023-02-17 |
| S-1 in Combination With Abraxane in Treating Cholangiocarcinoma S-1 plus Abraxane - Cholangiocarcinoma | Phase 2 | Completed | Yuhong Li | 50 | 2013-08-01 | 2018-02-05 |
| mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer mFOLFIRINOX - Metastatic Pancreatic Cancer | Phase 2 | Completed | Yuhong Li | 40 | 2013-02-01 | 2023-02-16 |
| FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma FOLFIRI - Advanced Esophageal Carcinoma | Phase 2 | Completed | Yuhong Li | 35 | 2012-03-01 | 2023-02-16 |
Esophageal Squamous Cell Carcinoma (4) · Colorectal Neoplasms (3) · Cholangiocarcinoma (1) · Pancreatic Neoplasms (1)
Fluorouracil (4) · Leucovorin (4) · Irinotecan (2) · Oxaliplatin (2) · Albumin-Bound Paclitaxel (1) · Capecitabine (1) · Cisplatin (1) · Dexamethasone (1) · Endostatins (1) · Floxuridine (1) · G(M1) Ganglioside (1) · IFL protocol (1) · Paclitaxel (1) · S 1 (combination) (1) · XELOX (1)
China (11)
Li Yuhong, MD (3) · Yu-hong Li, MD, Ph D (3) · Li Yuhong, Ph D (1) · Yu-hong Li (1)
PMID 31068222, PMID 31724334, PMID 34319435, PMID 37919448, PMID 42723578